Literature DB >> 225724

Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction.

R Dengler, R Rüdel, J Warelas, K L Birnberger.   

Abstract

The effect of prednisolone on indirectly stimulated rat muscle twitch was investigated at normal and prostigmine-treated neuromuscular junctions. In vivo, predenisolone up to 150 mg/kg body weight did not affect twitch contraction in normal animals. In neostigmine-pretreated animals, however, doses between 12.5 and 90 mg/kg could entirely abolish the anticholinesterase-induced twitch augmentation. In vitro, prednisolone produced a depressant effect on the twitch of a normal phrenic nerve diaphragm preparation which could amount to 20%. When the preparation was pretreated with neostigmine the augmented twitch could be depressed by 10(-3) to 10(-6) mol/l prednisolone to levels below the untreated control. Part of this effect is owing to a suppression of the neostigmine-induced, stimulus-bound repetitive firing of the motor nerve terminals, but to explain the full effect a further inhibitory action on neuromuscular transmission must be assumed. The latter could be accounted for by a depolarizing interaction of prednisolone and neostigmine on the nerve terminals resulting in conduction block. An action of prednisolone on postsynaptic receptors could also be considered. Such effects of the glucocorticoid might contribute to the exacerbation of muscular weakness occasionally observed in patients with myasthenia gravis at the beginning of steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225724     DOI: 10.1007/bf00582150

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  16 in total

1.  Glucocorticoids and mammalian motor nerve excitability.

Authors:  W F Riker; T Baker; M Okamoto
Journal:  Arch Neurol       Date:  1975-10

2.  ANTIDROMIC ACTIVITY IN THE RAT PHRENIC NERVE-DIAPHRAGM PREPARATION.

Authors:  M RANDIC; D W STRAUGHAN
Journal:  J Physiol       Date:  1964-09       Impact factor: 5.182

3.  The effects of depolarization of motor nerve terminals upon the release of transmitter by nerve impulses.

Authors:  J I Hubbard; W D Willis
Journal:  J Physiol       Date:  1968-02       Impact factor: 5.182

4.  Synthetic interstitial fluid for isolated mammalian tissue.

Authors:  A H Bretag
Journal:  Life Sci       Date:  1969-03-01       Impact factor: 5.037

5.  The effect of acetylcholine upon mammalian motor nerve terminals.

Authors:  J I Hubbard; R F Schmidt; T Yokota
Journal:  J Physiol       Date:  1965-12       Impact factor: 5.182

6.  Antimyasthenic action of corticosteroids.

Authors:  W W Hofmann
Journal:  Arch Neurol       Date:  1977-06

7.  The mechanism of action of anticholinesterases. II. The effect of diisopropylfluorophosphonate (DFP) on the isolated rat phrenic nervediaphragm preparation. A. Irreversible effects.

Authors:  C VAN DER MEER; E MEETER
Journal:  Acta Physiol Pharmacol Neerl       Date:  1956-03

8.  Effect of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. An experimental approach to a possible mechanism of action of corticosteroids in myasthenia gravis.

Authors:  R S Leeuwin; E C Wolters
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

9.  Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis.

Authors:  M J Wolters; R S Leeuwin
Journal:  Neurology       Date:  1976-06       Impact factor: 9.910

10.  Adverse interaction between steroid hormones and anticholinesterase drugs.

Authors:  B M Patten; K L Oliver; W K Engel
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

View more
  1 in total

1.  Sustained Neuromuscular Blockade after Vecuronium Use in a Premature Infant.

Authors:  Mitali Sahni; C Joan Richardson; Sunil K Jain
Journal:  AJP Rep       Date:  2015-05-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.